• Therapeutic Category
  • Pharmaceutical Form : Film Coated Tablets
  • Composition : Sparfloxacin 200 mg / Ctd. Tab
  • Active Substance : Sparfloxacin

SPARAFLOX is indicated for the treatment of adults (>18 year of age ) with the following infections caused by susceptibls strains of the designated microorganisms :Community-acquired pneumonia :
 caused by Chlamydia pneumonia , Haemophilus influenzae, Haemophilus parainfluenzae , Moraxclla catarrhalis , Mycoplasma pneumonia , or Streptococcus pneumoniae.
In pneumococcal or nonpneumococcal community-acquired pneumonia. Sparfloxacin has shown efficacy Similar to that of amoxicillin , erythromycin,roxithromycin , amoxicillin / clavulanic acid and amoxicillin Plus ofloxacin, and cefaclor, producing clinical cure rates of 80 to 84 %
Acute bacterial exacerbations of chronic bronchitis :
Caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus Parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus Aaureus, or Streptococcus Pneumoniae .
Sparfloxacin produced clinical efficacy rates of about 84 to 89% in several studies and the rates are similar to those achieved with amoxicillin, cefuroxime axetil, ofloxacin, claritromycin .
In surgical infections sparfloxacin produced clinical efficacy rates of 80.7%
It is also indicated in sexually transmitted disease including gonorrhea and chlamydia infections .
Gastrointestinal infections caused by shigella and salmonella Spp.
Urinary tract infections including urethritis, cystitis and pyelitis .
Skin and soft tissue infections including infected wounds , abscesses, pyoderma, cellulitis, furunculosis and Infective dermatitis .
Surgical infections caused by susceptible bacteria .
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and Identify organisms causing the infections and determine their susceptibility to Sparfloxacin .
Therapy with Sparaflox may be initiated before results of these tests are known , once results become available , appropriate therapy should be selected . Culture and susceptibility testing performed Periodically during therapy will provide information on the continued suseptibility of the pathogen to the antimicrobial agent and also on the possible emergence of bacterial resistance .
SPARAFLOX can be taken with or without food .
The recommended daily dose of SPARAFLOX in patients with normal renal functions is two SPARAFLOX 200mg tablets on the first day as a loading dose .
Thereafter , one SPARAFLOX 200 mg tablet should be taken every 24 hours for a total of 10 days of therapy .
The recommended daily dose of SPARAFLOX in patients with renal impairment
( creatinine clearance< 50ml/ min ) is two SPARAFLOX 200mg tablets taken on the first day as a loading dose .
Thereafter, one SPARAFLOX 200mg tablet Should be taken every 48 hours for a total of 9 days of therapy .